Barclays analyst Matt Miksic reiterated an Overweight rating and $104.00 price target on Medtronic, Inc. (NYSE: MDT).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE